News2024-11-19T14:15:11+00:00

NEWS 

2711, 2019

GABA Therapeutics Receives Approval to Begin Phase I Clinical Trials

Categories: Press Coverage, Uncategorized|

We are pleased to provide some positive updates. Inaugural Board Meeting The company held its first Board of Directors meeting in San Francisco in early November. Attendees included (left to right): Srini Rao M.D., Ph.D, Chief Medical Officer, GABA Therapeutics Ian Massey, D.Phil, CEO and Director, GABA Therapeutics Richard [...]

2009, 2019

GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

Categories: Press Coverage, Press Release|

NEWPORT BEACH, Calif. and BERLIN, Sept. 20, 2019 /PRNewswire/ -- Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences, a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space, announced a partnership to develop a novel compound that promises [...]

Go to Top